Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- You have a known BRCA1 or BRCA2 mutation (either inherited or found in the tumor).
- You are about to start Olaparib (a PARP inhibitor) as your first maintenance treatment, possibly with bevacizumab.
- You are 18 years or older.
- You have a good performance status (WHO score 0 or 1, meaning you are able to carry on normal activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This study is testing a new blood test that looks for cancer cells in your blood and checks if your tumor has a specific feature linked to DNA repair. The goal is to see if this blood test can help guide whether PARP inhibitor medicines—which target cancers with this feature—might work for you.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.